The Regulator of G-protein Signaling 10 (RGS10) is a member of the RGS protein family, which modulates G-protein-coupled receptor (GPCR) signaling by accelerating GTP hydrolysis on Gα subunits, thereby terminating downstream effector activation. RGS10 is highly expressed in the brain, particularly in regions like the striatum, hippocampus, and microglia, as well as in immune cells. It plays critical roles in neurodevelopment, inflammation, and cellular stress responses, with implications in neurodegenerative diseases (e.g., Parkinson’s and Alzheimer’s), cancer, and autoimmune disorders. RGS10 antibodies are essential tools for studying its expression, localization, and function. These antibodies enable detection via techniques such as Western blotting, immunohistochemistry, and immunofluorescence. Researchers use them to explore RGS10’s involvement in pathways like apoptosis, cytokine signaling, and neuroprotection. Specificity validation (e.g., knockout controls) is crucial, as RGS10 shares homology with other RGS proteins. Dysregulation of RGS10 has been linked to pathological states, making its antibodies valuable for both basic research and potential therapeutic target identification. Commercial RGS10 antibodies are typically developed in hosts like rabbits or mice, targeting unique epitopes within its conserved RGS domain or variable N-/C-terminal regions.